Page 2347 - Williams Hematology ( PDFDrive )

2320 Part XII: Hemostasis and Thrombosis Chapter 135: Fibrinolysis and Thrombolysis 2321

143. Redlitz A, Tan AK, Eaton D, Plow EF: Plasma carboxypeptidases as regulators of the 179. Falcone DJ, Borth W, Faisal Khan KM, Hajjar KA: Plasminogen-mediated matrix inva-
plasminogen system. J Clin Invest 96:2534–2538, 1995. sion and degradation by macrophages is dependent on surface expression of annexin II.
144. Miles LA, Dahlberg CM, Plescia J, et al: Role of cell surface lysines in plasminogen Blood 97:777–784, 2001.
binding to cells: Identification of alpha-enolase as a candidate plasminogen receptor. 180. Brownstein C, Deora AB, Jacovina AT, et al: Annexin II mediates plasminogen-
Biochemistry 30:1682–1691, 1991. dependent matrix invasion by human monocytes: Enhanced expression by macro-
145. Miles LA, Ginsberg MA, White JG, Plow EF: Plasminogen interacts with platelets phages. Blood 103:317–324, 2004.
through two distinct mechanisms. J Clin Invest 77:2001–2009, 1986. 181. Menell JS, Cesarman GM, Jacovina AT, et al: Annexin II and bleeding in acute promy-
146. Kanalas JJ, Makker SP: Identification of the rat Heymann nephritis autoantigen elocytic leukemia. N Engl J Med 340:994–1004, 1999.
(GP330) as a receptor site for plasminogen. J Biol Chem 266:10825–10829, 1991. 182. Lee TH, Rhim. T, Kim SS: Prothrombin kringle 2 domain has a growth inhibitory activ-
147. Barnathan ES, Kuo A, Van der Keyl H, et al: Tissue-type plasminogen activator bind- ity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol
ing to human endothelial cells: Evidence for two distinct binding sites. J Biol Chem Chem 273:28805–28812, 1998.
263:7792–7799, 1988. 183. Tressler RJ, Updyke TV, Yeatman TJ, Nicolson GL: Extracellular annexin is associated
148. Hajjar KA: The endothelial cell tissue plasminogen activator receptor: Specific interac- with divalent cation-dependent tumor cell adhesion of metastatic RAW 117 large-cell
tion with plasminogen. J Biol Chem 266:21962–21970, 1991. lymphoma cells. J Cell Biochem 53:265–276, 1993.
149. Hajjar KA, Hamel NM: Identification and characterization of human endothelial cell 184. Yeatman TJ, Updyke TV, Kaetzel MA, et al: Expression of annexins on the surfaces of
membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem non-metastatic human and rodent tumor cells. Clin Exp Metastasis 11:37–44, 1993.
265:2908–2916, 1990. 185. Tressler RJ, Nicolson GL: Butanol-extractable and detergent-solubilized cell surface
150. Das R, Burke T, Plow EF: Histone H2B as a functionally important plasminogen recep- components from murine large cell lymphoma cells associated with adhesion to organ
tor on macrophages. Blood 110:3763–3772, 2007. microvessel endothelial cells. J Cell Biochem 48:162–171, 1992.
151. Lighvani S, Baik N, Diggs JE, et al: Regulation of macrophage migration by a novel 186. Swairjo MA, Seaton BA: Annexin structure and membrane interactions: A molecular
plasminogen receptor Plg-R . Blood 118:5622–5630, 2011. perspective. Annu Rev Biophys Biomol Struct 23:193–213, 1994.
KT
152. D’Alessio S, Blasi F: The urokinase receptor as an entertainer of signal transduction. 187. Spano F, Raugei G, Palla E, et al: Characterization of the human lipocortin-2-encoding
Front Biosci 14:4575–4587, 2009. multigene family: Its structure suggests the existence of a short amino acid unit under-
153. Montuori N, Ragno P: Multiple activities of a multifaceted receptor: Roles of cleaved going duplication. Gene 95:243–251, 1990.
and soluble uPAR. Front Biosci 14:2492–2503, 2009. 188. Cesarman GM, Guevara CA, Hajjar KA: An endothelial cell receptor for plasminogen/
154. Roldan AL, Cubellis MV, Masucci MT, et al: Cloning and expression of the receptor for tissue plasminogen activator: II. Annexin II-mediated enhancement of t-PA-dependent
human urokinase plasminogen activator, a central molecule in cell surface, plasmin- plasminogen activation. J Biol Chem 269:21198–21203, 1994.
dependent proteolysis. EMBO J 9:467–474, 1990. 189. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA: An annexin 2 phosphorylation switch
155. Casey JR, Petranka JG, Kottra J, et al: The structure of the urokinase-type plasminogen mediates its p11-dependent translocation to the cell surface. J Biol Chem 279:43411–
activator receptor gene. Blood 84:1151–1156, 1994. 43418, 2004.
156. Behrendt N, Ronne E, Ploug M, et al: The human receptor for urokinase plasminogen 190. Hajjar KA, Guevara CA, Lev E, et al: Interaction of the fibrinolytic receptor, annexin
receptor. J Biol Chem 265:6453–6460, 1990. II, with the endothelial cell surface: Essential role of endonexin repeat 2. J Biol Chem
157. Ploug M, Ronne E, Behrendt N, et al: Cellular receptor for urokinase plasminogen acti- 271:21652–21659, 1996.
vator. Carboxyl-terminal processing and membrane anchoring by glycosylphosphati- 191. He K, Deora AB, Xiong H, et al: Endothelial cell annexin A2 regulates polyubiquiti-
dylinositol. J Biol Chem 266:1926–1933, 1991. nation and degradation of its binding partner, S100A10/p11. J Biol Chem 283:19192–
158. Cubellis MV, Andreasson P, Ragno P, et al: Accessibility of receptor-bound urokinase to 19200, 2008.
type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A 86:4828–4832, 1989. 192. Hajjar KA, Gavish D, Breslow J, Nachman RL: Lipoprotein(a) modulation of endothelial
159. Ellis V, Wun TC, Behrendt N, et al: Inhibition of receptor-bound urokinase by plas- cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303–305, 1989.
minogen activator inhibitor. J Biol Chem 265:9904–9908, 1990. 193. Hajjar KA, Mauri L, Jacovina AT, et al: Tissue plasminogen activator binding to the
160. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of annexin II tail domain: Direct modulation by homocysteine. J Biol Chem 273:9987–
urokinase is caused by its specific inhibitor PAI-1. EMBO J 9:1079–1085, 1990. 9993, 1998.
161. Ellis V, Behrendt N, Dano K: Plasminogen activation by receptor-bound urokinase. 194. Kraus JP: Molecular basis of phenotype expression in homocystinuria. J Inherit Metab
J Biol Chem 266:12752–12758, 1991. Dis 17:383–390, 1994.
162. Kugler MC, Wei Y, Chapman HA: Urokinase receptor and integrin interactions. Curr 195. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of
Pharm Des 9:1565–1574, 2003. plasma homocysteine as a risk factor for vascular disease. JAMA 274:1049–1057, 1995.
163. Bugge TH, Suh TT, Flick MJ, et al: The receptor for urokinase-type plasminogen acti- 196. Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular dis-
vator is not essential for mouse development or fertility. J Biol Chem 270:16886–16894, ease. Annu Rev Med 49:31–62, 1998.
1995. 197. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding
164. Dewerchin M, Van Nuffelen A, Wallays G, et al: Generation and characterization of to its endothelial cell membrane receptor. J Clin Invest 91:2873–2879, 1993.
urokinase receptor-deficient mice. J Clin Invest 97:870–878, 1996. 198. Jacovina AT, Deora AB, Ling Q, et al: Homocysteine inhibits neoangiogenesis in mice
165. Waltz DA, Chapman HA: Reversible cellular adhesion to vitronectin linked to uroki- through blockade of annexin A2-dependent fibrinolysis. J Clin Invest 119:3384–3394, 2009.
nase receptor occupancy. J Biol Chem 269:14746–14750, 1994. 199. Surette AP, Madureira PA, Phipps KD, et al: Regulation of fibrinolysis by S100A10 in
166. Wei Y, Waltz DA, Rao N, et al: Identification of the urokinase receptor as an adhesion vivo. Blood 118:3172–3181, 2011.
receptor for vitronectin. J Biol Chem 269:32380–32388, 1994. 200. O’Connell PA, Surette AP, Liwski RS, et al: S100A10 regulates plasminogen-dependent
167. Wei Y, Lukashev M, Simon DI, et al: Regulation of integrin function by the urokinase macrophage invasion. Blood 116:1136–1146, 2010.
receptor. Science 273:1551–1555, 1996. 201. O’Connell PA, Madureira PA, Berman JN, et al: Regulation of S100A10 by the
168. Xue W, Kindzelskii AL, Todd RF, Petty HR: Physical association of complement PML-RARalpha oncoprotein. Blood 117:4095–4105, 2011.
receptor type 3 and urokinase-type plasminogen activator in neutrophil membranes. 202. Ishii H, Yoshida M, Hiraoka M, et al: Recombinant annexin II modulates impaired
J Immunol 152:4630–4640, 1994. fibrinolytic activity in vitro and in rat carotid artery. Circ Res 89:1240–1245, 2001.
169. Stahl A, Mueller BM: The urokinase-type plasminogen activator receptor, a GPI-linked 203. Cesarman-Maus G, Cantu-Brito C, Barinagarrementeria F, et al: Autoantibodies
protein, is localized in caveolae. J Cell Biol 129:335–344, 1995. against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke
170. Anderson RG: Caveolae: Where incoming and outgoing messengers meet. Proc Natl 42:501–503, 2011.
Acad Sci U S A 90:10909–10913, 1993. 204. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al: Autoantibodies against the fibrino-
171. Okamoto T, Schlegel A, Scherer PE, Lisanti MP: Caveolins, a family of scaffolding lytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107:4375–4382, 2006.
proteins for organizing “preassembled signaling complexes” at the plasma membrane. 205. Ling Q, Jacovina AT, Deora AB, et al: Annexin II is a key regulator of fibrin homeostasis
J Biol Chem 273:5419–5422, 1998. and neoangiogenesis. J Clin Invest 113:38–48, 2004.
172. Gerke V, Creutz CE, Moss SE: Annexins: Linking Ca++ signalling to membrane 206. Bu G, Warshawsky I, Schwartz AL: Cellular receptors for the plasminogen activators.
dynamics. Nat Rev Mol Cell Biol 6(6):449–461, 2005. Blood 83:3427–3436, 1994.
173. Flood EC, Hajjar KA: The annexin A2 system and vascular homeostasis. Vascul Phar- 207. Lillis AP, Van Duyn LB, Murphy-Ullrich J, Strickland DK: LDL receptor-related protein
macol 54:59–67, 2011. 1: Unique tissue-specific functions revealed by selective gene knockout studies. Physiol
174. Luo M, Hajjar KA: Annexin A2 system in human biology: Cell surface and beyond. Rev 88:887–918, 2008.
Semin Thromb Hemost 39(4):338–346, 2013. 208. Herz J, Goldstein JL, Strickland DK, et al: 39 kDa protein modulates binding of ligands
175. Chung CY, Erickson HP: Cell surface annexin II is a high affinity receptor for the alter- to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor.
natively spliced segment of tenascin-C. J Cell Biol 126:539–548, 1994. J Biol Chem 266:21232–21238, 1991.
176. Wright JF, Kurosky A, Wasi S: An endothelial cell-surface form of annexin II binds 209. Herz J, Clouthier DE, Hammer RE: LDL receptor-related protein internalizes and
human cytomegalovirus. Biochem Biophys Res Commun 198:983–989, 1994. degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71:
177. Kassam G, Choi KS, Ghuman J, et al: The role of annexin II tetramer in the activation 411–421, 1992.
of plasminogen. J Biol Chem 273:4790–4799, 1998. 210. Herz J, Clouthier DE, Hammer RE: Correction: LDL receptor-related protein internal-
178. Siever DA, Erickson HP: Extracellular annexin II. Int J Biochem Cell Biol 29:1219–1223, izes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell
1997. 73:428, 1993.

Kaushansky_chapter 135_p2303-2326.indd 2321 9/18/15 5:14 PM